Efficacy and safety of switching from the DPP-4 inhibitor sitagliptin to the human GLP-1 analog liraglutide after 52 weeks in metformin-treated patients with type 2 diabetes: a randomized, open-label trial.
Saved in:
| Title: | Efficacy and safety of switching from the DPP-4 inhibitor sitagliptin to the human GLP-1 analog liraglutide after 52 weeks in metformin-treated patients with type 2 diabetes: a randomized, open-label trial. |
|---|---|
| Authors: | Pratley RE (AUTHOR), Nauck MA (AUTHOR), Bailey T (AUTHOR), Montanya E (AUTHOR), Filetti S (AUTHOR), Garber AJ (AUTHOR), Thomsen AB (AUTHOR), Furber S (AUTHOR), Davies M (AUTHOR), 1860-LIRA-DPP-4 Study Group (CORPORATE AUTHOR), Pratley, Richard E1 (AUTHOR), Nauck, Michael A (AUTHOR), Bailey, Timothy (AUTHOR), Montanya, Eduard (AUTHOR), Filetti, Sebastiano (AUTHOR), Garber, Alan J (AUTHOR), Thomsen, Anne B (AUTHOR), Furber, Sabina (AUTHOR), Davies, Melanie (AUTHOR) |
| Source: | Diabetes Care. Oct2012, Vol. 35 Issue 10, p1986-1993. 8p. |
| Database: | Academic Search Ultimate |
Be the first to leave a comment!
